Search

Your search keyword '"Cole Wayant"' showing total 2 results
Start Over Author "Cole Wayant" Journal chest
2 results on '"Cole Wayant"'

1. The Potential Effects of Financial Conflicts of Interest of Speakers at the US Food and Drug Administration’s Pulmonary-Allergy Drug Advisory Committee Meetings

Author

Nicholas Kinder, Wade Arthur, Trevor Bickford, Matt Vassar, and Cole Wayant

Subjects
Pulmonary and Respiratory Medicine, Drug, medicine.medical_specialty, Allergy, Advisory committee, media_common.quotation_subject, Advisory Committees, MEDLINE, Critical Care and Intensive Care Medicine, Food and drug administration, Internal medicine, Anti-Allergic Agents, Hypersensitivity, medicine, Humans, media_common, Conflict of Interest, United States Food and Drug Administration, business.industry, Congresses as Topic, medicine.disease, United States, Pulmonology, Family medicine, Cardiology and Cardiovascular Medicine, business
Published
2021
Full Text
View/download PDF

2. How Fragile Are Clinical Trial Outcomes That Support the CHEST Clinical Practice Guidelines for VTE?

Author

Elizabeth Edwards, Jonathan Besas, Justin Chronister, Matt Vassar, and Cole Wayant

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Disease, 030204 cardiovascular system & hematology, Critical Care and Intensive Care Medicine, law.invention, 03 medical and health sciences, 0302 clinical medicine, Fragility, Randomized controlled trial, Interquartile range, law, Antithrombotic, Outcome Assessment, Health Care, Medicine, Humans, Thrombolytic Therapy, 030212 general & internal medicine, Intensive care medicine, Randomized Controlled Trials as Topic, business.industry, Guideline, Venous Thromboembolism, Clinical trial, Practice Guidelines as Topic, Biostatistics, Cardiology and Cardiovascular Medicine, business
Abstract

Background VTE remains a health concern for global populations. Clinical practice guidelines are necessary to guide physicians in the prophylaxis and treatment of VTE. Methods Our investigation assessed the robustness of the underlying evidence in 21 randomized controlled trials (RCTs) used to support treatment recommendations in the 2016 update of the CHEST Guideline and Expert Panel Report on Antithrombotic Therapy for VTE Disease. We calculated the fragility index and fragility quotient for qualifying outcomes within RCTs. Results The median fragility index for all studies was 5 (interquartile range, 1-9), with a median fragility quotient of 0.012 (interquartile range, 0.002-0.032). Conclusions Our conclusions parallel those of previous investigations of the fragility of RCT outcomes; we found that some outcomes used to support recommendations in AT10 are fragile. We recommend that the fragility index and fragility quotient be adopted as measures of robustness of clinical trial outcomes.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results